Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib + Nab-paclitaxel + Gemcitabine in Metastatic Pancreatic Cancer
NCT02101021Phase 3Terminated
- Sponsor
- GSK
- Start
- Jun 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of momelotinib dihydrochloride in pancreatic ductal adenocarcinoma (PDAC), sponsored by GSK. Started Jun 2014; status: terminated.
02
Drugs
momelotinib dihydrochloride
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02101021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101021.